<?xml version="1.0" ?>
<!DOCTYPE PubmedArticleSet PUBLIC "-//NLM//DTD PubMedArticle, 1st January 2023//EN" "https://dtd.nlm.nih.gov/ncbi/pubmed/out/pubmed_230101.dtd">
<PubmedArticleSet>
<PubmedArticle><MedlineCitation Status="Publisher" Owner="NLM" IndexingMethod="Automated"><PMID Version="1">37799345</PMID><DateRevised><Year>2023</Year><Month>10</Month><Day>06</Day></DateRevised><Article PubModel="Electronic-eCollection"><Journal><ISSN IssnType="Electronic">2572-9241</ISSN><JournalIssue CitedMedium="Internet"><Volume>7</Volume><Issue>10</Issue><PubDate><Year>2023</Year><Month>Oct</Month></PubDate></JournalIssue><Title>HemaSphere</Title><ISOAbbreviation>Hemasphere</ISOAbbreviation></Journal><ArticleTitle>Clinical Implications and Dynamics of Clonal Hematopoiesis in Anti-CD19 CAR T-cell Treated Patients.</ArticleTitle><Pagination><StartPage>e957</StartPage><MedlinePgn>e957</MedlinePgn></Pagination><ELocationID EIdType="pii" ValidYN="Y">e957</ELocationID><ELocationID EIdType="doi" ValidYN="Y">10.1097/HS9.0000000000000957</ELocationID><Abstract><AbstractText>Recent evidence revealed important interactions between clonal hematopoiesis (CH) and cellular therapies established for the treatment of hematologic malignancies. The impact of CH on safety, efficacy, and outcome of chimeric antigen receptor (CAR) T-cell therapy is currently under investigation. We analyzed 110 patients with relapsed/refractory B-cell non-Hodgkin lymphoma (n = 105) or acute lymphoblastic leukemia (ALL) (n = 5), treated with Axicabtagene-Ciloleucel (39%), Tisagenlecleucel (51%), or Brexucabtagene autoleucel (10%). Using error-corrected targeted sequencing, a high CH prevalence of 56.4% (variant allele frequency [VAF] &#x2265;1%) at the time of CAR T-cell infusion was detected. The most frequently mutated gene was <i>PPM1D</i> followed by <i>DNMT3A</i>, <i>TET2</i>, <i>ASXL1</i>, and <i>TP53</i>. Variant allele frequencies were significantly lower in B and T cells compared with monocytes and granulocytes. CH did not increase the risk of CAR T-related toxicities. The incidences of cytokine release syndrome and immune effector-cell-associated neurotoxicity syndrome were similar between CH<sup>pos</sup> and CH<sup>neg</sup> patients, regardless of clone size, age, or CAR T product. Prolonged cytopenias were not associated with CH. Best overall response rates (ORRs) were numerically but not significantly higher in CH<sup>pos</sup> patients (ORR 76.7% versus 62.2%; <i>P</i> = 0.13). Furthermore, CH status did not predict progression-free survival or overall survival. Lastly, sequential analysis showed a modest VAF increase of 1.3% and acquisition of novel mutations within 100 days postinfusion. CH was frequent in large B-cell lymphoma/ALL patients receiving CAR T-cells but did not affect toxicity nor treatment response or outcome.</AbstractText><CopyrightInformation>Copyright &#xa9; 2023 the Author(s). Published by Wolters Kluwer Health, Inc. on behalf of the European Hematology Association.</CopyrightInformation></Abstract><AuthorList CompleteYN="Y"><Author ValidYN="Y"><LastName>Panagiota</LastName><ForeName>Victoria</ForeName><Initials>V</Initials><AffiliationInfo><Affiliation>Department of Hematology, Hemostasis, Oncology and Stem Cell Transplantation, Hannover Medical School, Hannover, Germany.</Affiliation></AffiliationInfo></Author><Author ValidYN="Y"><LastName>Kerschbaum</LastName><ForeName>Johanna Franziska</ForeName><Initials>JF</Initials><AffiliationInfo><Affiliation>Department of Hematology, Oncology, and Cancer Immunology, Charit&#xe9; - Universit&#xe4;tsmedizin Berlin, corporate member of Freie Universit&#xe4;t Berlin, Humboldt-Universit&#xe4;t zu Berlin, Germany.</Affiliation></AffiliationInfo></Author><Author ValidYN="Y"><LastName>Penack</LastName><ForeName>Olaf</ForeName><Initials>O</Initials><AffiliationInfo><Affiliation>Department of Hematology, Oncology, and Cancer Immunology, Charit&#xe9; - Universit&#xe4;tsmedizin Berlin, corporate member of Freie Universit&#xe4;t Berlin, Humboldt-Universit&#xe4;t zu Berlin, Germany.</Affiliation></AffiliationInfo></Author><Author ValidYN="Y"><LastName>Stein</LastName><ForeName>Catarina M</ForeName><Initials>CM</Initials><AffiliationInfo><Affiliation>Department of Hematology, Oncology, and Cancer Immunology, Charit&#xe9; - Universit&#xe4;tsmedizin Berlin, corporate member of Freie Universit&#xe4;t Berlin, Humboldt-Universit&#xe4;t zu Berlin, Germany.</Affiliation></AffiliationInfo></Author><Author ValidYN="Y"><LastName>Arends</LastName><ForeName>Christopher M</ForeName><Initials>CM</Initials><AffiliationInfo><Affiliation>Department of Hematology, Oncology, and Cancer Immunology, Charit&#xe9; - Universit&#xe4;tsmedizin Berlin, corporate member of Freie Universit&#xe4;t Berlin, Humboldt-Universit&#xe4;t zu Berlin, Germany.</Affiliation></AffiliationInfo><AffiliationInfo><Affiliation>Berlin Institute of Health at Charit&#xe9; - Universit&#xe4;tsmedizin Berlin, Germany.</Affiliation></AffiliationInfo></Author><Author ValidYN="Y"><LastName>Koenecke</LastName><ForeName>Christian</ForeName><Initials>C</Initials><AffiliationInfo><Affiliation>Department of Hematology, Hemostasis, Oncology and Stem Cell Transplantation, Hannover Medical School, Hannover, Germany.</Affiliation></AffiliationInfo></Author><Author ValidYN="Y"><LastName>Strzelecka</LastName><ForeName>Paulina M</ForeName><Initials>PM</Initials><AffiliationInfo><Affiliation>Department of Hematology, Oncology, and Cancer Immunology, Charit&#xe9; - Universit&#xe4;tsmedizin Berlin, corporate member of Freie Universit&#xe4;t Berlin, Humboldt-Universit&#xe4;t zu Berlin, Germany.</Affiliation></AffiliationInfo></Author><Author ValidYN="Y"><LastName>Kloos</LastName><ForeName>Arnold</ForeName><Initials>A</Initials><AffiliationInfo><Affiliation>Department of Hematology, Hemostasis, Oncology and Stem Cell Transplantation, Hannover Medical School, Hannover, Germany.</Affiliation></AffiliationInfo></Author><Author ValidYN="Y"><LastName>Wiegand</LastName><ForeName>Laura</ForeName><Initials>L</Initials><AffiliationInfo><Affiliation>Department of Hematology, Oncology, and Cancer Immunology, Charit&#xe9; - Universit&#xe4;tsmedizin Berlin, corporate member of Freie Universit&#xe4;t Berlin, Humboldt-Universit&#xe4;t zu Berlin, Germany.</Affiliation></AffiliationInfo></Author><Author ValidYN="Y"><LastName>Lasch</LastName><ForeName>Alina</ForeName><Initials>A</Initials><AffiliationInfo><Affiliation>Department of Hematology, Hemostasis, Oncology and Stem Cell Transplantation, Hannover Medical School, Hannover, Germany.</Affiliation></AffiliationInfo></Author><Author ValidYN="Y"><LastName>Altwasser</LastName><ForeName>Robert</ForeName><Initials>R</Initials><AffiliationInfo><Affiliation>Department of Hematology, Oncology, and Cancer Immunology, Charit&#xe9; - Universit&#xe4;tsmedizin Berlin, corporate member of Freie Universit&#xe4;t Berlin, Humboldt-Universit&#xe4;t zu Berlin, Germany.</Affiliation></AffiliationInfo></Author><Author ValidYN="Y"><LastName>Halik</LastName><ForeName>Adriane</ForeName><Initials>A</Initials><AffiliationInfo><Affiliation>Department of Hematology, Oncology, and Cancer Immunology, Charit&#xe9; - Universit&#xe4;tsmedizin Berlin, corporate member of Freie Universit&#xe4;t Berlin, Humboldt-Universit&#xe4;t zu Berlin, Germany.</Affiliation></AffiliationInfo><AffiliationInfo><Affiliation>Berlin Institute of Health at Charit&#xe9; - Universit&#xe4;tsmedizin Berlin, Germany.</Affiliation></AffiliationInfo></Author><Author ValidYN="Y"><LastName>Gabdoulline</LastName><ForeName>Razif</ForeName><Initials>R</Initials><AffiliationInfo><Affiliation>Department of Hematology, Hemostasis, Oncology and Stem Cell Transplantation, Hannover Medical School, Hannover, Germany.</Affiliation></AffiliationInfo></Author><Author ValidYN="Y"><LastName>Thomson</LastName><ForeName>Julia</ForeName><Initials>J</Initials><AffiliationInfo><Affiliation>Department of Hematology and Medical Oncology, University Medicine G&#xf6;ttingen, Germany.</Affiliation></AffiliationInfo></Author><Author ValidYN="Y"><LastName>Weibl</LastName><ForeName>Konstantin</ForeName><Initials>K</Initials><AffiliationInfo><Affiliation>Medical Clinic and Policlinic 1, Hematology, Cellular Therapy and Hemostaseology, University of Leipzig Medical Center, Leipzig, Germany.</Affiliation></AffiliationInfo></Author><Author ValidYN="Y"><LastName>Franke</LastName><ForeName>Georg-Nikolaus</ForeName><Initials>GN</Initials><AffiliationInfo><Affiliation>Medical Clinic and Policlinic 1, Hematology, Cellular Therapy and Hemostaseology, University of Leipzig Medical Center, Leipzig, Germany.</Affiliation></AffiliationInfo></Author><Author ValidYN="Y"><LastName>Berger</LastName><ForeName>Carolina</ForeName><Initials>C</Initials><AffiliationInfo><Affiliation>Department of Stem Cell Transplantation, University Medical Center Hamburg-Eppendorf, Germany.</Affiliation></AffiliationInfo></Author><Author ValidYN="Y"><LastName>Hasenkamp</LastName><ForeName>Justin</ForeName><Initials>J</Initials><AffiliationInfo><Affiliation>Department of Hematology and Medical Oncology, University Medicine G&#xf6;ttingen, Germany.</Affiliation></AffiliationInfo></Author><Author ValidYN="Y"><LastName>Ayuk</LastName><ForeName>Francis</ForeName><Initials>F</Initials><AffiliationInfo><Affiliation>Department of Stem Cell Transplantation, University Medical Center Hamburg-Eppendorf, Germany.</Affiliation></AffiliationInfo></Author><Author ValidYN="Y"><LastName>Na</LastName><ForeName>Il-Kang</ForeName><Initials>IK</Initials><AffiliationInfo><Affiliation>Department of Hematology, Oncology, and Cancer Immunology, Charit&#xe9; - Universit&#xe4;tsmedizin Berlin, corporate member of Freie Universit&#xe4;t Berlin, Humboldt-Universit&#xe4;t zu Berlin, Germany.</Affiliation></AffiliationInfo><AffiliationInfo><Affiliation>Berlin Institute of Health at Charit&#xe9; - Universit&#xe4;tsmedizin Berlin, Germany.</Affiliation></AffiliationInfo><AffiliationInfo><Affiliation>German Cancer Consortium (DKTK), Partner Site Berlin, Germany.</Affiliation></AffiliationInfo><AffiliationInfo><Affiliation>Charit&#xe9; - Universit&#xe4;tsmedizin Berlin, Corporate Member of Freie Universit&#xe4;t Berlin and Humboldt Universit&#xe4;t zu Berlin, ECRC Experimental and Clinical Research Center, Berlin, Germany.</Affiliation></AffiliationInfo></Author><Author ValidYN="Y"><LastName>Beutel</LastName><ForeName>Gernot</ForeName><Initials>G</Initials><AffiliationInfo><Affiliation>Department of Hematology, Hemostasis, Oncology and Stem Cell Transplantation, Hannover Medical School, Hannover, Germany.</Affiliation></AffiliationInfo></Author><Author ValidYN="Y"><LastName>Keller</LastName><ForeName>Ulrich</ForeName><Initials>U</Initials><AffiliationInfo><Affiliation>Department of Hematology, Oncology, and Cancer Immunology, Charit&#xe9; - Universit&#xe4;tsmedizin Berlin, corporate member of Freie Universit&#xe4;t Berlin, Humboldt-Universit&#xe4;t zu Berlin, Germany.</Affiliation></AffiliationInfo><AffiliationInfo><Affiliation>German Cancer Consortium (DKTK), Partner Site Berlin, Germany.</Affiliation></AffiliationInfo><AffiliationInfo><Affiliation>German Cancer Research Center (DKFZ), Heidelberg, Germany.</Affiliation></AffiliationInfo><AffiliationInfo><Affiliation>Max-Delbr&#xfc;ck-Center for Molecular Medicine, Berlin, Germany.</Affiliation></AffiliationInfo></Author><Author ValidYN="Y"><LastName>Bullinger</LastName><ForeName>Lars</ForeName><Initials>L</Initials><AffiliationInfo><Affiliation>Department of Hematology, Oncology, and Cancer Immunology, Charit&#xe9; - Universit&#xe4;tsmedizin Berlin, corporate member of Freie Universit&#xe4;t Berlin, Humboldt-Universit&#xe4;t zu Berlin, Germany.</Affiliation></AffiliationInfo><AffiliationInfo><Affiliation>Berlin Institute of Health at Charit&#xe9; - Universit&#xe4;tsmedizin Berlin, Germany.</Affiliation></AffiliationInfo><AffiliationInfo><Affiliation>German Cancer Consortium (DKTK), Partner Site Berlin, Germany.</Affiliation></AffiliationInfo><AffiliationInfo><Affiliation>German Cancer Research Center (DKFZ), Heidelberg, Germany.</Affiliation></AffiliationInfo></Author><Author ValidYN="Y"><LastName>Wulf</LastName><ForeName>Gerald Georg</ForeName><Initials>GG</Initials><AffiliationInfo><Affiliation>Department of Hematology and Medical Oncology, University Medicine G&#xf6;ttingen, Germany.</Affiliation></AffiliationInfo></Author><Author ValidYN="Y"><LastName>Kr&#xf6;ger</LastName><ForeName>Nicolaus</ForeName><Initials>N</Initials><AffiliationInfo><Affiliation>Department of Stem Cell Transplantation, University Medical Center Hamburg-Eppendorf, Germany.</Affiliation></AffiliationInfo></Author><Author ValidYN="Y"><LastName>Vucinic</LastName><ForeName>Vladan</ForeName><Initials>V</Initials><AffiliationInfo><Affiliation>Medical Clinic and Policlinic 1, Hematology, Cellular Therapy and Hemostaseology, University of Leipzig Medical Center, Leipzig, Germany.</Affiliation></AffiliationInfo></Author><Author ValidYN="Y"><LastName>Heuser</LastName><ForeName>Michael</ForeName><Initials>M</Initials><AffiliationInfo><Affiliation>Department of Hematology, Hemostasis, Oncology and Stem Cell Transplantation, Hannover Medical School, Hannover, Germany.</Affiliation></AffiliationInfo></Author><Author ValidYN="Y"><LastName>Damm</LastName><ForeName>Frederik</ForeName><Initials>F</Initials><AffiliationInfo><Affiliation>Department of Hematology, Oncology, and Cancer Immunology, Charit&#xe9; - Universit&#xe4;tsmedizin Berlin, corporate member of Freie Universit&#xe4;t Berlin, Humboldt-Universit&#xe4;t zu Berlin, Germany.</Affiliation></AffiliationInfo><AffiliationInfo><Affiliation>Berlin Institute of Health at Charit&#xe9; - Universit&#xe4;tsmedizin Berlin, Germany.</Affiliation></AffiliationInfo><AffiliationInfo><Affiliation>German Cancer Consortium (DKTK), Partner Site Berlin, Germany.</Affiliation></AffiliationInfo><AffiliationInfo><Affiliation>German Cancer Research Center (DKFZ), Heidelberg, Germany.</Affiliation></AffiliationInfo></Author></AuthorList><Language>eng</Language><PublicationTypeList><PublicationType UI="D016428">Journal Article</PublicationType></PublicationTypeList><ArticleDate DateType="Electronic"><Year>2023</Year><Month>10</Month><Day>03</Day></ArticleDate></Article><MedlineJournalInfo><Country>United States</Country><MedlineTA>Hemasphere</MedlineTA><NlmUniqueID>101740619</NlmUniqueID><ISSNLinking>2572-9241</ISSNLinking></MedlineJournalInfo><CoiStatement>MH reports fees for advisory or consultancy services from Abbvie, Agios, BMS, Daiichi Sankyo, Eurocept, Glycostem, Janssen, Jazz Pharmaceuticals, Kura Oncology, Novartis, Pfizer, PinotBio, Roche, Takeda, and Tolremo. FD reports personal fees from Gilead, Incyte, Roche, Novartis, AbbVie, Astra Zeneca outside the submitted work. JFK reports personal fees from Gilead and Janssen outside the submitted work. GW reports honoraria from Gilead, Novartis, Clinigen, and Janssen outside the submitted work. OP has no conflicts of interest directly related to this work. OP has received honoraria or travel support from Gilead, Jazz, MSD, Novartis, Pfizer, and Therakos. He has received research support from Incyte and Priothera. He is member of advisory boards to Equillium Bio, Jazz, Gilead, Novartis, MSD, Omeros, Priothera, Sanofi, Shionogi, and SOBI. All the other authors have no conflicts of interest to disclose.</CoiStatement></MedlineCitation><PubmedData><History><PubMedPubDate PubStatus="received"><Year>2023</Year><Month>3</Month><Day>30</Day></PubMedPubDate><PubMedPubDate PubStatus="accepted"><Year>2023</Year><Month>8</Month><Day>8</Day></PubMedPubDate><PubMedPubDate PubStatus="medline"><Year>2023</Year><Month>10</Month><Day>6</Day><Hour>6</Hour><Minute>43</Minute></PubMedPubDate><PubMedPubDate PubStatus="pubmed"><Year>2023</Year><Month>10</Month><Day>6</Day><Hour>6</Hour><Minute>43</Minute></PubMedPubDate><PubMedPubDate PubStatus="entrez"><Year>2023</Year><Month>10</Month><Day>6</Day><Hour>3</Hour><Minute>48</Minute></PubMedPubDate></History><PublicationStatus>epublish</PublicationStatus><ArticleIdList><ArticleId IdType="pubmed">37799345</ArticleId><ArticleId IdType="pmc">PMC10550045</ArticleId><ArticleId IdType="doi">10.1097/HS9.0000000000000957</ArticleId></ArticleIdList><ReferenceList><Reference><Citation>Abelson S, Collord G, Ng SWK, et al. . Prediction of acute myeloid leukaemia risk in healthy individuals. Nature. 2018;559:400&#x2013;404.</Citation><ArticleIdList><ArticleId IdType="pmc">PMC6485381</ArticleId><ArticleId IdType="pubmed">29988082</ArticleId></ArticleIdList></Reference><Reference><Citation>Acuna-Hidalgo R, Sengul H, Steehouwer M, et al. . Ultra-sensitive sequencing identifies high prevalence of clonal hematopoiesis-associated mutations throughout adult life. Am J Hum Genet. 2017;101:50&#x2013;64.</Citation><ArticleIdList><ArticleId IdType="pmc">PMC5501773</ArticleId><ArticleId IdType="pubmed">28669404</ArticleId></ArticleIdList></Reference><Reference><Citation>Arends CM, Weiss M, Christen F, et al. . Clonal hematopoiesis in patients with anti-neutrophil cytoplasmic antibody-associated vasculitis. Haematologica. 2020;105:e264&#x2013;e267.</Citation><ArticleIdList><ArticleId IdType="pmc">PMC7271609</ArticleId><ArticleId IdType="pubmed">31582546</ArticleId></ArticleIdList></Reference><Reference><Citation>Buscarlet M, Provost S, Zada YF, et al. . DNMT3A and TET2 dominate clonal hematopoiesis and demonstrate benign phenotypes and different genetic predispositions. Blood. 2017;130:753&#x2013;762.</Citation><ArticleIdList><ArticleId IdType="pubmed">28655780</ArticleId></ArticleIdList></Reference><Reference><Citation>Bolton KL, Ptashkin RN, Gao T, et al. . Cancer therapy shapes the fitness landscape of clonal hematopoiesis. Nat Genet. 2020;52:1219&#x2013;1226.</Citation><ArticleIdList><ArticleId IdType="pmc">PMC7891089</ArticleId><ArticleId IdType="pubmed">33106634</ArticleId></ArticleIdList></Reference><Reference><Citation>Coombs CC, Zehir A, Devlin SM, et al. . Therapy-related clonal hematopoiesis in patients with non-hematologic cancers is common and associated with adverse clinical outcomes. Cell Stem Cell. 2017;21:374&#x2013;382.e4.</Citation><ArticleIdList><ArticleId IdType="pmc">PMC5591073</ArticleId><ArticleId IdType="pubmed">28803919</ArticleId></ArticleIdList></Reference><Reference><Citation>Jaiswal S, Fontanillas P, Flannick J, et al. . Age-related clonal hematopoiesis associated with adverse outcomes. N Engl J Med. 2014;371:2488&#x2013;2498.</Citation><ArticleIdList><ArticleId IdType="pmc">PMC4306669</ArticleId><ArticleId IdType="pubmed">25426837</ArticleId></ArticleIdList></Reference><Reference><Citation>Fuster JJ, MacLauchlan S, Zuriaga MA, et al. . Clonal hematopoiesis associated with TET2 deficiency accelerates atherosclerosis development in mice. Science. 2017;355:842&#x2013;847.</Citation><ArticleIdList><ArticleId IdType="pmc">PMC5542057</ArticleId><ArticleId IdType="pubmed">28104796</ArticleId></ArticleIdList></Reference><Reference><Citation>Jaiswal S, Natarajan P, Silver AJ, et al. . Clonal hematopoiesis and risk of atherosclerotic cardiovascular disease. N Engl J Med. 2017;377:111&#x2013;121.</Citation><ArticleIdList><ArticleId IdType="pmc">PMC6717509</ArticleId><ArticleId IdType="pubmed">28636844</ArticleId></ArticleIdList></Reference><Reference><Citation>Sano S, Oshima K, Wang Y, et al. . Tet2-mediated clonal hematopoiesis accelerates heart failure through a mechanism involving the IL-1beta/NLRP3 inflammasome. J Am Coll Cardiol. 2018;71:875&#x2013;886.</Citation><ArticleIdList><ArticleId IdType="pmc">PMC5828038</ArticleId><ArticleId IdType="pubmed">29471939</ArticleId></ArticleIdList></Reference><Reference><Citation>Christen F, Hablesreiter R, Hoyer K, et al. . Modeling clonal hematopoiesis in umbilical cord blood cells by CRISPR/Cas9. Leukemia. 2022;36:1102&#x2013;1110.</Citation><ArticleIdList><ArticleId IdType="pmc">PMC8979818</ArticleId><ArticleId IdType="pubmed">34782715</ArticleId></ArticleIdList></Reference><Reference><Citation>Furer N, Kaushansky N, Shlush LI. The vicious and virtuous circles of clonal hematopoiesis. Nat Med. 2021;27:949&#x2013;950.</Citation><ArticleIdList><ArticleId IdType="pubmed">34099925</ArticleId></ArticleIdList></Reference><Reference><Citation>Gibson CJ, Lindsley RC, Tchekmedyian V, et al. . Clonal hematopoiesis associated with adverse outcomes after autologous stem-cell transplantation for lymphoma. J Clin Oncol. 2017;35:1598&#x2013;1605.</Citation><ArticleIdList><ArticleId IdType="pmc">PMC5455707</ArticleId><ArticleId IdType="pubmed">28068180</ArticleId></ArticleIdList></Reference><Reference><Citation>Neelapu SS, Locke FL, Bartlett NL, et al. . Axicabtagene ciloleucel CAR T-cell therapy in refractory large B-cell lymphoma. N Engl J Med. 2017;377:2531&#x2013;2544.</Citation><ArticleIdList><ArticleId IdType="pmc">PMC5882485</ArticleId><ArticleId IdType="pubmed">29226797</ArticleId></ArticleIdList></Reference><Reference><Citation>Schuster SJ, Bishop MR, Tam CS, et al. . Tisagenlecleucel in adult relapsed or refractory diffuse large B-cell lymphoma. N Engl J Med. 2019;380:45&#x2013;56.</Citation><ArticleIdList><ArticleId IdType="pubmed">30501490</ArticleId></ArticleIdList></Reference><Reference><Citation>Miller PG, Sperling AS, Brea EJ, et al. . Clonal hematopoiesis in patients receiving chimeric antigen receptor T-cell therapy. Blood Adv. 2021;5:2982&#x2013;2986.</Citation><ArticleIdList><ArticleId IdType="pmc">PMC8361461</ArticleId><ArticleId IdType="pubmed">34342642</ArticleId></ArticleIdList></Reference><Reference><Citation>Saini NY, Swoboda DM, Greenbaum U, et al. . Clonal hematopoiesis is associated with increased risk of severe neurotoxicity in axicabtagene ciloleucel therapy of large B-cell lymphoma. Blood Cancer Discov. 2022;3:385&#x2013;393.</Citation><ArticleIdList><ArticleId IdType="pmc">PMC9445749</ArticleId><ArticleId IdType="pubmed">35533245</ArticleId></ArticleIdList></Reference><Reference><Citation>Teipel R, Kroschinsky F, Kramer M, et al. . Prevalence and variation of CHIP in patients with aggressive lymphomas undergoing CD19-directed CAR T-cell treatment. Blood Adv. 2022;6:1941&#x2013;1946.</Citation><ArticleIdList><ArticleId IdType="pmc">PMC8941459</ArticleId><ArticleId IdType="pubmed">35008107</ArticleId></ArticleIdList></Reference><Reference><Citation>Fraietta JA, Nobles CL, Sammons MA, et al. . Disruption of TET2 promotes the therapeutic efficacy of CD19-targeted T cells. Nature. 2018;558:307&#x2013;312.</Citation><ArticleIdList><ArticleId IdType="pmc">PMC6320248</ArticleId><ArticleId IdType="pubmed">29849141</ArticleId></ArticleIdList></Reference><Reference><Citation>Lee DW, Santomasso BD, Locke FL, et al. . ASTCT consensus grading for cytokine release syndrome and neurologic toxicity associated with immune effector cells. Biol Blood Marrow Transplant. 2019;25:625&#x2013;638.</Citation><ArticleIdList><ArticleId IdType="pubmed">30592986</ArticleId></ArticleIdList></Reference><Reference><Citation>Neelapu SS, Tummala S, Kebriaei P, et al. . Chimeric antigen receptor T-cell therapy - assessment and management of toxicities. Nat Rev Clin Oncol. 2018;15:47&#x2013;62.</Citation><ArticleIdList><ArticleId IdType="pmc">PMC6733403</ArticleId><ArticleId IdType="pubmed">28925994</ArticleId></ArticleIdList></Reference><Reference><Citation>Arends CM, Dimitriou S, Stahler A, et al. . Clonal hematopoiesis is associated with improved survival in patients with metastatic colorectal cancer from the FIRE-3 trial. Blood. 2022;139:1593&#x2013;1597.</Citation><ArticleIdList><ArticleId IdType="pubmed">34932794</ArticleId></ArticleIdList></Reference><Reference><Citation>Arends CM, Liman TG, Strzelecka PM, et al. . Associations of clonal haematopoiesis with recurrent vascular events and death in patients with incident ischemic stroke. Blood. 2023;141:787&#x2013;799.</Citation><ArticleIdList><ArticleId IdType="pubmed">36441964</ArticleId></ArticleIdList></Reference><Reference><Citation>Frick M, Chan W, Arends CM, et al. . Role of donor clonal hematopoiesis in allogeneic hematopoietic stem-cell transplantation. J Clin Oncol. 2019;37:375&#x2013;385.</Citation><ArticleIdList><ArticleId IdType="pubmed">30403573</ArticleId></ArticleIdList></Reference><Reference><Citation>Heuser M, Heida B, B&#xfc;ttner K, et al. . Posttransplantation MRD monitoring in patients with AML by next-generation sequencing using DTA and non-DTA mutations. Blood Adv. 2021;5:2294&#x2013;2304.</Citation><ArticleIdList><ArticleId IdType="pmc">PMC8114555</ArticleId><ArticleId IdType="pubmed">33929500</ArticleId></ArticleIdList></Reference><Reference><Citation>Crump M, Neelapu SS, Farooq U, et al. . Outcomes in refractory diffuse large B-cell lymphoma: results from the international SCHOLAR-1 study. Blood. 2017;130:1800&#x2013;1808.</Citation><ArticleIdList><ArticleId IdType="pmc">PMC5649550</ArticleId><ArticleId IdType="pubmed">28774879</ArticleId></ArticleIdList></Reference><Reference><Citation>Alaggio R, Amador C, Anagnostopoulos I, et al. . The 5th edition of the World Health Organization Classification of Haematolymphoid Tumours: Lymphoid Neoplasms. Leukemia. 2022;36:1720&#x2013;1748.</Citation><ArticleIdList><ArticleId IdType="pmc">PMC9214472</ArticleId><ArticleId IdType="pubmed">35732829</ArticleId></ArticleIdList></Reference><Reference><Citation>Arends CM, Galan-Sousa J, Hoyer K, et al. . Hematopoietic lineage distribution and evolutionary dynamics of clonal hematopoiesis. Leukemia. 2018;32:1908&#x2013;1919.</Citation><ArticleIdList><ArticleId IdType="pubmed">29491455</ArticleId></ArticleIdList></Reference><Reference><Citation>Hartmann L, Hecker JS, Rothenberg-Thurley M, et al. . Compartment-specific mutational landscape of clonal hematopoiesis. Leukemia. 2022;36:2647&#x2013;2655.</Citation><ArticleIdList><ArticleId IdType="pmc">PMC9613457</ArticleId><ArticleId IdType="pubmed">36131041</ArticleId></ArticleIdList></Reference><Reference><Citation>Locke FL, Ghobadi A, Jacobson CA, et al. . Long-term safety and activity of axicabtagene ciloleucel in refractory large B-cell lymphoma (ZUMA-1): a single-arm, multicentre, phase 1-2 trial. Lancet Oncol. 2019;20:31&#x2013;42.</Citation><ArticleIdList><ArticleId IdType="pmc">PMC6733402</ArticleId><ArticleId IdType="pubmed">30518502</ArticleId></ArticleIdList></Reference><Reference><Citation>Munshi NC, Anderson LD, Jr, Shah N, et al. . Idecabtagene vicleucel in relapsed and refractory multiple myeloma. N Engl J Med. 2021;384:705&#x2013;716.</Citation><ArticleIdList><ArticleId IdType="pubmed">33626253</ArticleId></ArticleIdList></Reference><Reference><Citation>Wang M, Munoz J, Goy A, et al. . KTE-X19 CAR T-cell therapy in relapsed or refractory mantle-cell lymphoma. N Engl J Med. 2020;382:1331&#x2013;1342.</Citation><ArticleIdList><ArticleId IdType="pmc">PMC7731441</ArticleId><ArticleId IdType="pubmed">32242358</ArticleId></ArticleIdList></Reference><Reference><Citation>Hormaechea-Agulla D, Matatall KA, Le DT, et al. . Chronic infection drives Dnmt3a-loss-of-function clonal hematopoiesis via IFNgamma signaling. Cell Stem Cell. 2021;28:1428&#x2013;1442.e6.</Citation><ArticleIdList><ArticleId IdType="pmc">PMC8349829</ArticleId><ArticleId IdType="pubmed">33743191</ArticleId></ArticleIdList></Reference><Reference><Citation>Bachy E, Le Gouill S, Di Blasi R, et al. . A real-world comparison of tisagenlecleucel and axicabtagene ciloleucel CAR T cells in relapsed or refractory diffuse large B cell lymphoma. Nat Med. 2022;28:2145&#x2013;2154.</Citation><ArticleIdList><ArticleId IdType="pmc">PMC9556323</ArticleId><ArticleId IdType="pubmed">36138152</ArticleId></ArticleIdList></Reference><Reference><Citation>Jain N, Zhao Z, Feucht J, et al. . TET2 guards against unchecked BATF3-induced CAR T cell expansion. Nature. 2023;615:315&#x2013;322.</Citation><ArticleIdList><ArticleId IdType="pmc">PMC10511001</ArticleId><ArticleId IdType="pubmed">36755094</ArticleId></ArticleIdList></Reference></ReferenceList></PubmedData></PubmedArticle></PubmedArticleSet>